Drug Trial Radar · NCT06235242
GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2
Actual
Start
Feb 2, 2024
Primary completion
Dec 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Grit BiotechnologyIndustry
- Sponsor type
- Industry
- First posted
- Jan 31, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single arm, open design aimed at evaluating the safety and tolerability of Autologous Tumor-Infiltrating Lymphocyte (GT201 injection ) in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer,while evaluating pharmacokinetic characteristics and efficacy assessment to determine the optimal biological dose (OBD).
Conditions
- Adult
- Non-small Cell Lung Cancer
Interventions
GT201 injection in combination with teraplizumab injectionBiological
GT201 injection in combination with teraplizumab injection for treatment of patients with non-small cell lung cancer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Profile Measured by Grade ≥3 TRAEsTime frame: 3 years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Beijing Gobroad Hospital
Beijing, Beijing Municipality, China
Shanghai East Hospital
Shanghai, Shanghai Municipality, China
Shanghai GoBroad Cancer Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.